It is also noteworthy that some of the therapeutic approaches used for MS, such as steroid therapy, interferon beta (IFNβ) therapy or natalizumab, induce a decrease in IL-1β levels in the CSF while increasing IL-1 levels in the blood [10]. This evidence concerns the gene IL1A and myeloid sarcoma.